Treatment of HIV-associated Kaposi's sarcoma with paclitaxel

@article{Saville1995TreatmentOH,
  title={Treatment of HIV-associated Kaposi's sarcoma with paclitaxel},
  author={M. Wayne Saville and J A Lietzau and James M. Pluda and Wyndham H Wilson and Rachel W. Humphrey and Ellen Feigel and S. M. Steinberg and Samuel E. Broder and Robert Yarchoan and Jeanne Odom and Irwin M. Feuerstein},
  journal={The Lancet},
  year={1995},
  volume={346},
  pages={26-28}
}
Paclitaxel for AIDS-associated Kaposi’s sarcoma
TLDR
The use of paclitaxel in these circumstances is reviewed and the management of early stage cutaneous AIDS-KS has been revolutionized by the introduction of highly active antiretroviral therapy.
Chemotherapy of AIDS--related Kaposi's sarcoma.
Successful treatment with paclitaxel of advanced AIDS-associated Kaposi's sarcoma.
TLDR
A 44-year-old Japanese man with advanced AIDS-associated KS, which was spread over bilateral pulmonary parenchyma, is reported, which suggests that paclitaxel was highly effective for KS disease control as previously reported, and that immune restoration with HAART is crucial in the treatment of KS.
Activity of thalidomide in AIDS-related Kaposi's sarcoma.
  • R. Little, K. Wyvill, R. Yarchoan
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2000
TLDR
Oral thalidomide was tolerated in this population at doses up to 1,000 mg/d for as long as 12 months and was found to induce clinically meaningful anti-KS responses in a sizable subset of the patients.
Recent Advances in the Treatment of AIDS-Related Kaposi’s Sarcoma
TLDR
In general, systemic treatment for KS is limited to widespread, symptomatic disease, whereas local interventions are indicated for minimal, cosmetically troublesome lesions, and the identification of a novel γ-herpesvirus, human herpesvirus-8, as a causative agent for KS, together with novel antiangiogenic compounds, may offer promising targets for the therapy of KS.
Docetaxel in anthracycline‐pretreated AIDS‐related Kaposi's sarcoma: a retrospective study
TLDR
The use of Liposomal anthracyclines or combination chemotherapy in patients with Kaposi's sarcoma is widely used but adverse effects limit their utilization.
First‐line treatment with paclitaxel for non‐HIV‐related Kaposi sarcoma: experience in 10 cases
TLDR
The experience concerning the efficacy and toxicity of paclitaxel as a first-line treatment in aggressive non-HIV-related KS is described and the response according to the AIDS Clinical Trials Group criteria is reported.
Acquired immunodeficiency syndrome-associated Kaposi's sarcoma. Biology and management.
  • S. Krown
  • Medicine, Biology
    The Medical clinics of North America
  • 1997
Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma.
  • A. Tulpule, D. Scadden, P. Gill
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2000
TLDR
IM862 given as intranasal drops is well tolerated and has antitumor activity in patients with AIDS-KS.
...
...

References

SHOWING 1-10 OF 10 REFERENCES
Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee.
  • S. Krown, C. Metroka, J. Wernz
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1989
TLDR
Recommendations include a standardized format for documenting the extent of KS on initial and subsequent evaluations, response definitions that include assessments of lesion nodularity and tumor-associated edema in addition to more traditional methods for evaluating tumor response, and a new staging system that includes extent of tumor, immune status, and other AIDS-related disease manifestations.
Immunological variables as predictors of prognosis in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome.
TLDR
It is concluded that immunological parameters may be useful in predicting prognosis in patients with Kaposi's sarcoma and acquired immunodeficiency syndrome treated with recombinant leukocyte A interferon.
Effect of race on expression of acquired immunodeficiency syndrome-associated nephropathy.
TLDR
Differences in host responses to viral proteins, physiologic adaptations, or socioeconomic factors in these populations may play an important role in mediating the expression of renal disease in individual patients.
Paclitaxel (Taxol) in breast cancer.
Textbook of AIDS Medicine
TLDR
A immunologist's view of HIV infection, a paradigm of AIDS malignancies AIDS-associated malignant lymphomas and ethics diseases associated with other retroviruses human immunodeficience virus type-2 HTLV-1 andHTLV-2.
The calculation of received dose intensity.
  • W. Hryniuk, M. Goodyear
  • Physics
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1990